Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx Nexavar Fails Phase III Melanoma Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Onyx is continuing its melanoma program despite sorafenib’s failure to show a progression-free survival benefit in an advanced melanoma study.

You may also be interested in...



Nexavar Long Term Opportunities Are In Breast, Lung Cancer, Onyx CEO Renton Says

A search is underway for a new CEO to take the helm of the drug maker after Renton’s planned retirement next year.

Nexavar Long Term Opportunities Are In Breast, Lung Cancer, Onyx CEO Renton Says

A search is underway for a new CEO to take the helm of the drug maker after Renton’s planned retirement next year.

Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer

Companies will submit sNDA as soon as possible following study halt because of “superior overall survival efficacy.”

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel